Pancreatic Cancer, a new study from Decision Resources, Inc., explains why the coming decade will be an active period for companies developing and refining therapies to treat this highly virulent disease.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION ) Novel Agents Spur Market Growth
Experts interviewed for Pancreatic Cancer consider epidermal growth factor (EGF) inhibitors to be one of the most promising approaches in current pancreatic cancer (PC) research. The most promising EGF inhibitors -- trastuzumab (Genentech/Roche's Herceptin) and cetuximab (ImClone Systems/Bristol-Myers Squibb/Merck KGaA's Erbitux) -- will compete for market share as such therapies become established in PC treatment.
Clinicians interviewed for this report are very excited about the potential of trastuzumab in treating PC patients who overexpress the HER-2 oncogene. The report projects that trastuzumab will be approved for PC early in the second half of our forecast period and that it will be widely used in combination with gemcitabine as first-line therapy in appropriate patients, and as monotherapy in patients who cannot tolerate gemcitabine. Physicians interviewed for this report also believe that cetuximab could be effective in PC and that, if approved, it would be widely used in the 50-70% of patients who overexpress HER-1. Decision Resources anticipates that cetuximab, like trastuzumab, will be used both in combination with gemcitabine and as a single-agent therapy.
Among the therapeutic vaccines in development, the most promising are antigastrin 17 (Aphton/Aventis's Gastroimmune) and Virulizin (from Lorus Therapeutics). Because of their low toxicity, Decision Resources anticipates that therapeutic vaccines would be used in almost all PC patients, in addition to standard therapy. Also, the report projects that patients ineligible for gemcitabine or EGF inhibitor therapy because of a low performance status would be offered immunotherapy monotherapy.
Pancreatic Cancer offers invaluable market intelligence to pharmaceutical companies that are developing drugs to treat this disease. This study is part of Onkos, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.
Contact Frank Sama, 781.296.2553 (tel), 781.296.2550 (fax), or firstname.lastname@example.org
In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or email@example.com
In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or firstname.lastname@example.org
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, +1-781-296-2553, or